Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.

导出 OA

翻译打印收藏纠错

作者： Jun,Zhang ^[1] ; Melissa,Johnson ^[2] ; Minal,Barve ^[3] ; Lyudmila,Bazhenova ^[4] ; Marybeth,McCarthy ^[5] ; Rowena,Schwartz ^[6] ; Elise,Horvath-Walsh ^[7] ; Karen,Velastegui ^[7] ; Chunlin,Qian ^[7] ; Alexander,Spira ^[8]

作者单位： Division of Medical Oncology, Department of Internal Medicine, Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA. ^[1] Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN, USA. ^[2] Mary Crowley Cancer Research, Dallas, TX, USA. ^[3] UC San Diego Moores Cancer Center, La Jolla, CA, USA. ^[4] Thoracic Oncology Clinical Trials, Henry Ford Cancer Institute, Detroit, MI, USA. ^[5] University of Cincinnati, Cincinnati, OH, USA. ^[6] Mirati Therapeutics, Inc., San Diego, CA, USA. ^[7] Virginia Cancer Specialists, Fairfax, VA, USA. ^[8] NEXT Oncology Virginia, US Oncology Research, The Woodlands, TX, USA. ^[9]

关键词 KRASG12C mutation adagrasib adverse events management non-small cell lung cancer safety

主题词人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms);哌嗪类(Piperazines);乙腈类(Acetonitriles)

DOI 10.1093/oncolo/oyad051

PMID 36892150

发布时间 2023-04-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交